
Man charged with killing preborn child after allegedly shooting pregnant woman
Bridget Sielicki
·
Analysis·By Anne Marie Williams, RN, BSN
A study claims hormonal contraception improves brain health. Does it?
Can taking oral contraceptives during the reproductive years protect women’s cognitive health down the road, entering menopause and beyond? And even if hormonal contraceptives do slow down brain aging, should we still be cautious given the known mental health, cardiovascular and other risks that come with hormonal birth control use?
Longer reproductive lifespan, pregnancy, breastfeeding, and appropriately-timed menopause hormone therapy can all benefit women’s later-in-life cerebrovascular health.
A 2026 study conducted questionnaires and evaluated brain imaging studies in 352 Swedish women at age 70 and (for most) again at age 75.
The study showed that who had used oral contraceptives or menopause hormone therapy (MHT) or both generally tended to have better cerebrovascular health, though the effects of OC use were reduced after adjusting to reduce false positives.
The greatest benefit came from starting menopause late rather than from starting periods early.
Distinctions matter: oral contraceptives override the body’s natural hormonal rhythms in order to prevent ovulation, leading to lower levels of the body’s own estrogen and progesterone. MHT seeks to cooperatively ‘add back’ estrogen and progesterone that the body once made but is now making in much smaller quantities as menopause approaches. The dosages are not the same as oral contraceptive use, and the goal is supplementation rather than suppression.
Given the numerous risks of oral contraceptives — including but not limited to worsening mental health, benign brain tumors, elevated breast cancer risk, blood clot risk, heart attack risk, stroke risk — it is important to weight whether a modest improvement in cognitive health outweighs the significant risks of oral contraceptive use.
Here’s what we know based on a 2026 study and previous research.
We know that exposure to the body’s own estrogen helps protect cerebrovascular health, meaning having to do with the brain and its blood vessels (estrogen isn’t necessary and good for the reproductive system alone!). The longer a woman has periods, whether from starting her cycles early and/or entering menopause late, the more protective estrogen exposure she has.
If she conceives babies, she’s exposed to high levels of a different type of estrogen than when nonpregnant (estriol during pregnancy versus estradiol when not pregnant). Some research suggests that the more months a woman is pregnant, and also the longer she breastfeeds, the better her cognitive function later in life.
In contrast, pregnancy loss due to stillbirth is associated with higher risk of cognitive problems like dementia later in life; miscarriage is associated with cerebrovascular disease (like strokes).
And finally, if a woman’s estrogen supply suddenly and dramatically nosedives – as occurs if she has a bilateral oophorectomy, removal of both her ovaries – before the normal age range of menopause, her cognitive function tends to worsen.
The benefits of the body’s own estrogen are known, but what about estrogen from outside the body?
The two main kinds of exogenous estrogen are hormonal contraceptives (usually oral contraceptives are studied in the research) and hormonal replacement therapy, also known as menopause hormone therapy (MHT).
In a 2026 study published in the peer-reviewed journal Neurology, researchers conducted questionnaires and evaluated brain imaging studies in 352 Swedish women at age 70 and (for most) again at age 75.
They wanted to know how past use of oral contraceptives and past or current use of MHT impacted women’s markers of brain aging and cognitive decline.
They anticipated that exposure to estrogen from OC and MHT would be protective for women’s brains.
There’s one distinction we should make before we look at the study results, even though it’s a distinction not often made by researchers on this topic:
Oral contraceptives override the body’s natural hormonal rhythms in order to prevent ovulation (even though ovulation is a sign of whole-body health and a fifth vital sign for women), leading to lower levels of the body’s own estrogen and progesterone.
MHT, on the other hand, seeks to cooperatively ‘add back’ estrogen and progesterone that the body once made but is now making in much smaller quantities as menopause approaches. The dosages are not the same as oral contraceptive use, and the goal is supplementation rather than suppression. It makes sense that, when timed appropriately – in keeping with the ‘critical window hypothesis’ that recognizes a distinct window of opportunity in which it may help, and after which it may hurt – menopause hormone therapy could be a helpful tool.
Logically, one might expect that OC use wouldn’t benefit women in the same way as MHT use, especially since with OC they’re exposed to less of their bodies’ own estrogen as they receive more external estrogen.
But does it?
Overall, the results of the study were modest.
Predictably – given what we know about the body’s own estrogen protecting female brains – the longer a woman’s reproductive lifespan, the lower her chances of small vessel disease (disease in the small blood vessels of the brain).
The greatest benefit came from starting menopause late rather than from starting periods early.
Women who had used oral contraceptives or menopause hormone therapy or both generally tended to have better cerebrovascular health, though the effects of OC use were reduced after adjusting to reduce false positives.
In some but not all analyses, women who had both used OC at some point and taken MHT at some point had lower risk of small vessel disease and stronger white matter integrity (in charge of neuron communication in the brain and throughout the nervous system) compared to nonusers.
Specifically in carriers for APOE, the “strongest known genetic risk factor for Alzheimer’s disease,” MHT use but not OC use reduced vulnerability to Alzheimer’s Disease-related brain atrophy.
A significant limitation of the study was that OC and MHT use were measured as ‘ever’ or ‘never,’ without accounting for when women started taking them, how long they took them, etc.
While some research connects oral contraceptive use with improvements in certain markers of cognitive function, its connection with worsening mental health for vulnerable individuals is more well-established (at present we don’t have good ways to know in advance who will be vulnerable, though we know that women who struggled mentally on birth control may have higher postpartum depression risk down the road).
This is especially the case for adolescents.
We also know that certain types of birth control are associated with benign brain tumors (in this case, benign doesn’t mean ‘not dangerous,’ since they may still grow large enough to cause pressure on other parts of the brain and require surgery).
Hormonal birth control use can also deplete the body of key vitamins and minerals; raise breast cancer risk, blood clot risk, and heart attack and stroke risk (even for healthy, young users); may be abortifacient; alters stress responses; and deprives women of the whole-body benefits of ovulation.

We know that longer reproductive lifespan, pregnancy, breastfeeding, and appropriately timed MHT can all benefit women’s later-in-life cerebrovascular health.
It would be very important to weigh hormonal birth control’s potential cognitive benefits against its more widely-known negative health impacts.
Live Action News is pro-life news and commentary from a pro-life perspective.
Our work is possible because of our donors. Please consider giving to further our work of changing hearts and minds on issues of life and human dignity.
Contact editor@liveaction.org for questions, corrections, or if you are seeking permission to reprint any Live Action News content.
Guest Articles: To submit a guest article to Live Action News, email editor@liveaction.org with an attached Word document of 800-1000 words. Please also attach any photos relevant to your submission if applicable. If your submission is accepted for publication, you will be notified within three weeks. Guest articles are not compensated (see our Open License Agreement). Thank you for your interest in Live Action News!

Bridget Sielicki
·
Issues
Cassy Cooke
·
Analysis
Cassy Cooke
·
Analysis
Nancy Flanders
·
Fact Checks
Cassy Cooke
·
Investigative
Nancy Flanders
·
Human Interest
Anne Marie Williams, RN, BSN
·
Issues
Anne Marie Williams, RN, BSN
·
Issues
Anne Marie Williams, RN, BSN
·
Issues
Anne Marie Williams, RN, BSN
·
Opinion
Anne Marie Williams, RN, BSN
·
Analysis·By Anne Marie Williams, RN, BSN
A study claims hormonal contraception improves brain health. Does it?
Can taking oral contraceptives during the reproductive years protect women’s cognitive health down the road, entering menopause and beyond? And even if hormonal contraceptives do slow down brain aging, should we still be cautious given the known mental health, cardiovascular and other risks that come with hormonal birth control use?
Longer reproductive lifespan, pregnancy, breastfeeding, and appropriately-timed menopause hormone therapy can all benefit women’s later-in-life cerebrovascular health.
A 2026 study conducted questionnaires and evaluated brain imaging studies in 352 Swedish women at age 70 and (for most) again at age 75.
The study showed that who had used oral contraceptives or menopause hormone therapy (MHT) or both generally tended to have better cerebrovascular health, though the effects of OC use were reduced after adjusting to reduce false positives.
The greatest benefit came from starting menopause late rather than from starting periods early.
Distinctions matter: oral contraceptives override the body’s natural hormonal rhythms in order to prevent ovulation, leading to lower levels of the body’s own estrogen and progesterone. MHT seeks to cooperatively ‘add back’ estrogen and progesterone that the body once made but is now making in much smaller quantities as menopause approaches. The dosages are not the same as oral contraceptive use, and the goal is supplementation rather than suppression.
Given the numerous risks of oral contraceptives — including but not limited to worsening mental health, benign brain tumors, elevated breast cancer risk, blood clot risk, heart attack risk, stroke risk — it is important to weight whether a modest improvement in cognitive health outweighs the significant risks of oral contraceptive use.
Here’s what we know based on a 2026 study and previous research.
We know that exposure to the body’s own estrogen helps protect cerebrovascular health, meaning having to do with the brain and its blood vessels (estrogen isn’t necessary and good for the reproductive system alone!). The longer a woman has periods, whether from starting her cycles early and/or entering menopause late, the more protective estrogen exposure she has.
If she conceives babies, she’s exposed to high levels of a different type of estrogen than when nonpregnant (estriol during pregnancy versus estradiol when not pregnant). Some research suggests that the more months a woman is pregnant, and also the longer she breastfeeds, the better her cognitive function later in life.
In contrast, pregnancy loss due to stillbirth is associated with higher risk of cognitive problems like dementia later in life; miscarriage is associated with cerebrovascular disease (like strokes).
And finally, if a woman’s estrogen supply suddenly and dramatically nosedives – as occurs if she has a bilateral oophorectomy, removal of both her ovaries – before the normal age range of menopause, her cognitive function tends to worsen.
The benefits of the body’s own estrogen are known, but what about estrogen from outside the body?
The two main kinds of exogenous estrogen are hormonal contraceptives (usually oral contraceptives are studied in the research) and hormonal replacement therapy, also known as menopause hormone therapy (MHT).
In a 2026 study published in the peer-reviewed journal Neurology, researchers conducted questionnaires and evaluated brain imaging studies in 352 Swedish women at age 70 and (for most) again at age 75.
They wanted to know how past use of oral contraceptives and past or current use of MHT impacted women’s markers of brain aging and cognitive decline.
They anticipated that exposure to estrogen from OC and MHT would be protective for women’s brains.
There’s one distinction we should make before we look at the study results, even though it’s a distinction not often made by researchers on this topic:
Oral contraceptives override the body’s natural hormonal rhythms in order to prevent ovulation (even though ovulation is a sign of whole-body health and a fifth vital sign for women), leading to lower levels of the body’s own estrogen and progesterone.
MHT, on the other hand, seeks to cooperatively ‘add back’ estrogen and progesterone that the body once made but is now making in much smaller quantities as menopause approaches. The dosages are not the same as oral contraceptive use, and the goal is supplementation rather than suppression. It makes sense that, when timed appropriately – in keeping with the ‘critical window hypothesis’ that recognizes a distinct window of opportunity in which it may help, and after which it may hurt – menopause hormone therapy could be a helpful tool.
Logically, one might expect that OC use wouldn’t benefit women in the same way as MHT use, especially since with OC they’re exposed to less of their bodies’ own estrogen as they receive more external estrogen.
But does it?
Overall, the results of the study were modest.
Predictably – given what we know about the body’s own estrogen protecting female brains – the longer a woman’s reproductive lifespan, the lower her chances of small vessel disease (disease in the small blood vessels of the brain).
The greatest benefit came from starting menopause late rather than from starting periods early.
Women who had used oral contraceptives or menopause hormone therapy or both generally tended to have better cerebrovascular health, though the effects of OC use were reduced after adjusting to reduce false positives.
In some but not all analyses, women who had both used OC at some point and taken MHT at some point had lower risk of small vessel disease and stronger white matter integrity (in charge of neuron communication in the brain and throughout the nervous system) compared to nonusers.
Specifically in carriers for APOE, the “strongest known genetic risk factor for Alzheimer’s disease,” MHT use but not OC use reduced vulnerability to Alzheimer’s Disease-related brain atrophy.
A significant limitation of the study was that OC and MHT use were measured as ‘ever’ or ‘never,’ without accounting for when women started taking them, how long they took them, etc.
While some research connects oral contraceptive use with improvements in certain markers of cognitive function, its connection with worsening mental health for vulnerable individuals is more well-established (at present we don’t have good ways to know in advance who will be vulnerable, though we know that women who struggled mentally on birth control may have higher postpartum depression risk down the road).
This is especially the case for adolescents.
We also know that certain types of birth control are associated with benign brain tumors (in this case, benign doesn’t mean ‘not dangerous,’ since they may still grow large enough to cause pressure on other parts of the brain and require surgery).
Hormonal birth control use can also deplete the body of key vitamins and minerals; raise breast cancer risk, blood clot risk, and heart attack and stroke risk (even for healthy, young users); may be abortifacient; alters stress responses; and deprives women of the whole-body benefits of ovulation.

We know that longer reproductive lifespan, pregnancy, breastfeeding, and appropriately timed MHT can all benefit women’s later-in-life cerebrovascular health.
It would be very important to weigh hormonal birth control’s potential cognitive benefits against its more widely-known negative health impacts.
Live Action News is pro-life news and commentary from a pro-life perspective.
Our work is possible because of our donors. Please consider giving to further our work of changing hearts and minds on issues of life and human dignity.
Contact editor@liveaction.org for questions, corrections, or if you are seeking permission to reprint any Live Action News content.
Guest Articles: To submit a guest article to Live Action News, email editor@liveaction.org with an attached Word document of 800-1000 words. Please also attach any photos relevant to your submission if applicable. If your submission is accepted for publication, you will be notified within three weeks. Guest articles are not compensated (see our Open License Agreement). Thank you for your interest in Live Action News!

Bridget Sielicki
·
Issues
Cassy Cooke
·
Analysis
Cassy Cooke
·
Analysis
Nancy Flanders
·
Fact Checks
Cassy Cooke
·
Investigative
Nancy Flanders
·
Human Interest
Anne Marie Williams, RN, BSN
·
Issues
Anne Marie Williams, RN, BSN
·
Issues
Anne Marie Williams, RN, BSN
·
Issues
Anne Marie Williams, RN, BSN
·
Opinion
Anne Marie Williams, RN, BSN
·